0.98
-0.0434(-4.25%)
Currency In USD
| Previous Close | 1.02 |
| Open | 1.02 |
| Day High | 1.02 |
| Day Low | 0.97 |
| 52-Week High | 2.18 |
| 52-Week Low | 0.65 |
| Volume | 773,089 |
| Average Volume | 1.06M |
| Market Cap | 58.27M |
| PE | -0.47 |
| EPS | -2.1 |
| Moving Average 50 Days | 0.95 |
| Moving Average 200 Days | 1.08 |
| Change | -0.04 |
If you invested $1000 in Opus Genetics, Inc. (IRD) since IPO date, it would be worth $12,207.5 as of June 28, 2025 at a share price of $0.977. Whereas If you bought $1000 worth of Opus Genetics, Inc. (IRD) shares 0 years ago, it would be worth $757.05 as of June 28, 2025 at a share price of $0.977.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
GlobeNewswire Inc.
Jun 26, 2025 10:55 AM GMT
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuitySafety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the studyNo evid
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
GlobeNewswire Inc.
Jun 23, 2025 12:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small mole
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
GlobeNewswire Inc.
Jun 02, 2025 12:00 PM GMT
Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placeboPhase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairment in kerat